SCHEMBL20133113

SCHEMBL20133113

Cn1c2ccncc2c2ccc(-c3ccc(OC4CCN(C(=O)OC(C)(C)C)CC4)nc3)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 14/20 0.50
PIK3CD O00329 2/20 0.43
SGMS2 Q8NHU3 1/20 0.41
CACNB4 O00305 2/20 0.41
CACNA1A O00555 2/20 0.41
CACNA1G O43497 2/20 0.41
CACNG3 O60359 2/20 0.41
CACNA1F O60840 2/20 0.41
CACNA1H O95180 2/20 0.41
CACNB3 P54284 2/20 0.41
CACNA2D1 P54289 2/20 0.41
CACNG7 P62955 2/20 0.41
CACNA1B Q00975 2/20 0.41
CACNA1D Q01668 2/20 0.41
CACNB1 Q02641 2/20 0.41
CACNG1 Q06432 2/20 0.41
CACNB2 Q08289 2/20 0.41
CACNA1S Q13698 2/20 0.41
CACNA1C Q13936 2/20 0.41
CACNA1E Q15878 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27098515 0.92 GPR119 (0.42) GPR119PIK3CD
SCHEMBL27098541 0.92 GPR119 (0.42) GPR119PIK3CDSGMS2
SCHEMBL20129043 0.91 PIK3CD (0.41) GPR119PIK3CDCACNB4CACNA1ACACNA1G
SCHEMBL20132915 0.90 GPR119 (0.45) GPR119PIK3CDSGMS2
SCHEMBL27098289 0.88 GPR119 (0.45) GPR119PIK3CDSGMS2
SCHEMBL29548272 0.88 GPR119 (0.45) GPR119PIK3CDSGMS2
SCHEMBL27139946 0.88 GPR119 (0.45) GPR119PIK3CDSGMS2
SCHEMBL20129278 0.88 GPR119 (0.40) GPR119PIK3CDSGMS2CACNB4CACNA1A
SCHEMBL20129046 0.88 PIK3CD (0.39) GPR119PIK3CDSGMS2
SCHEMBL20133356 0.88 GPR119 (0.43) GPR119PIK3CDSGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN GPR119 3791/4885PIK3CD 2235/4885SGMS2 4756/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 GPR119 3741/4885PIK3CD 2652/4885SGMS2 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.